 Aptorum Group Limited APM went public through an initial public offering which closed in December 2018 and raised 12.0M gross from the sale of 761k common shares. The shares were added to the Morgan Stanley Capital International MSCI Hong Kong Micro Cap Index in May 2019. Aptorum is a Hong Kong based pre-revenue company focused on the development and eventual commercialization of a range of therapeutics in neurology, infectious diseases, gastroenterology, oncology and other disease areas. 